Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
810 NX-1607, a small molecule inhibitor of CBL-B, enhances anti-PD-1-mediated tumor growth inhibition by reshaping intratumoral innate and adaptive immune response
Compose a Response to This Article
Other responses
No responses have been published for this article.